Clinical Trials Logo

Bacterial Infection clinical trials

View clinical trials related to Bacterial Infection.

Filter by:

NCT ID: NCT02544230 Completed - Sepsis Clinical Trials

Granulocyte Transfusions in Hematological Patients With Febrile Neutropenia

Start date: January 2004
Phase: N/A
Study type: Observational

The investigators retrospectively evaluated the efficacy of granulocyte transfusions as adjunctive treatment for severe infections in neutropenic fever unresponsive to antimicrobial therapy in hematological patients.

NCT ID: NCT02436876 Completed - Bacterial Infection Clinical Trials

Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites

Start date: May 24, 2016
Phase: Phase 2
Study type: Interventional

This study evaluates the safety and clinical benefit of MBN-101 administered intraoperatively to osteosynthesis or osteomyelitis sites for patients diagnosed with an orthopedic infection, with or without orthopaedic hardware. Three quarters of the patients will receive MBN-101, while the other one quarter will receive placebo.

NCT ID: NCT02375477 Completed - Clinical trials for Clostridium Difficile

Improved Adherence to C. Difficile Isolation Protocols Through Improved Education Methods

Start date: January 27, 2015
Phase: N/A
Study type: Interventional

This clinical trial studies how well inter-disciplinary educational methods work in improving adherence to isolation protocols in patients with Clostridium (C.) difficile infections. An inter-disciplinary educational method may help to prevent the spread of infection.

NCT ID: NCT02311816 Completed - Bacterial Infection Clinical Trials

Increase in Procalcitonin Kinetics May be a Good Indicator of Starting Empirical Antibiotic Treatment in Critically Ill Patients

Start date: October 2012
Phase: N/A
Study type: Observational

The value of procalcitonin change from the day before to the day when infection was suspected in predicting bacterial infection in intensive care patients.

NCT ID: NCT02294175 Completed - Bacterial Infection Clinical Trials

Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm

Start date: January 2015
Phase: N/A
Study type: Interventional

This is a prospective study of Veterans with chronic lower extremity or diabetic foot ulcers who will be randomized to either a Larval Debridement Therapy group (Biobags every 4 days x 2 applications) or a Sharp Debridement Therapy group (standard or control weekly x 2) during an 8 day study period.

NCT ID: NCT02268279 Completed - Bacterial Infection Clinical Trials

Pharmacokinetics and Safety of Solithromycin in Adolescents and Children

Start date: January 2015
Phase: Phase 1
Study type: Interventional

Pediatric study to evaluate the safety and pharmacokinetics of solithromycin (oral and intravenous) in children ages 0 to 17

NCT ID: NCT02052388 Completed - Bacterial Infection Clinical Trials

Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

Start date: February 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of three different dosing regimens of brilacidin compared to daptomycin for the treatment of serious skin infections. This study will aid in selecting the appropriate dose of brilacidin for later stage studies.

NCT ID: NCT01892358 Completed - HIV Clinical Trials

Preventing Bacterial and Viral Infections Among Injection Drug Users

Start date: September 2013
Phase: N/A
Study type: Interventional

We propose a randomized controlled trial (RCT) of the Skin intervention, compared to an assessment-only condition (both groups receive rapid HIV testing, a review of testing results, and brief HIV prevention counseling) among 350 injection drug users recruited during an acute medical hospitalization at Boston Medical Center. In the general hospital setting, injection drug users who otherwise might not seek care are accessible and teachable, and the presence of a drug-related illness can set the stage for patients to be more receptive to interventions2. We hypothesize that the Skin intervention will produce better outcomes at 1-, 3-, 6-, 9-, and 12-month(s) post-intervention.

NCT ID: NCT01817075 Completed - Malignant Neoplasm Clinical Trials

Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

Start date: November 4, 2013
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies chlorhexidine gluconate cleansing to see how well it works compared to control cleansing in preventing central line associated bloodstream infection and acquisition of multi-drug resistant organisms in younger patients with cancer or undergoing donor stem cell transplant. Chlorhexidine gluconate may help reduce bloodstream infections and bacterial infections associated with the central line.

NCT ID: NCT01803100 Completed - Bacterial Infection Clinical Trials

Characterizing and Comparing the Profile of Microorganisms From Specific Body Sites and Environmental Surfaces in Newly Disinfected Patient Rooms

Start date: January 2013
Phase: N/A
Study type: Observational

Overall Aim: To describe and to assess the change in the temporal profile and transmission of microorganisms between patients and environmental surfaces after admission into a newly disinfected room. Study Activities: Investigators will prospectively and concurrently perform microbiological sampling of body sites (nose, throat, axillae, perineal and wounds) high touch surfaces (e.g. bedside rail, bed surface, toilet seat, IV pump and tray table) for consented adult patients admitted to freshly cleaned patient rooms. The microbiological sampling of body sites is already performed in many units of the hospital as standard of care. Infection and readmission related data from enrolled patients will be collected for upto 1 year after enrollment. Data analysis: Standard surveillance for hospital-acquired infections will be performed by the infection control group of the hospital. The identity and the nature of micro-organisms colonizing the high touch surfaces of rooms and of patient's body sites will be determined and compared. Risks involved is no more than minimal risk.